PCA3 molecular urine assay for prostate cancer: Association with pathologic features and impact of collection protocols

World Journal of Urology

Volumn 29, Issue 5, 2011, Pages 683-688

  Liss, Michael A ^a   Santos, Rosanne ^a   Osann, Kathryn ^a   Lau, Alice ^a   Ahlering, Thomas E ^a   Ornstein, David K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b 21ST CENTURY ONCOLOGY   (United States)

Author keywords

Biological; Diagnosis; Gene expression; Prostate cancer; Prostate specific antigen; Tumor marker

Indexed keywords

PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

ARTICLE; DIGITAL RECTAL EXAMINATION; HUMAN; LABORATORY DIAGNOSIS; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR; URINE;

ANTIGENS, NEOPLASM; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SPECIMEN HANDLING;

EID: 80053652425     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0623-6     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4): 225-249. doi: 10. 3322/caac. 20006.
2. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8): 725-732. doi: 10. 1016/S1470-2045(10)70146-7.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13): 1320-1328. doi: 10. 1056/NEJMoa0810084.
4. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HH Jr (2001) The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2. 5 and 4. 0 ng/ml: relation to biopsy strategy. J Urol 165(3): 757-760.
5. Catalona WJ, Smith DS, Ornstein DK (1997) Prostate cancer detection in men with serum PSA concentrations of 2. 6 to 4. 0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277(18): 1452-1455.
6. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44(1): 8-15; discussion 15-16.
7. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA (2002) DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62(9): 2695-2698.
8. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Masse B, Piche L, Chypre C (2004) uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64(2): 311-315; discussion 315-316. doi: 10. 1016/j. urology. 2004. 03. 052.
9. van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA (2007) Molecular PCA3 diagnostics on prostatic fluid. Prostate 67(8): 881-887. doi: 10. 1002/pros. 20564.
10. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG (2008) PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180(5): 1975-1978; discussion 1978-1979. doi: 10. 1016/j. juro. 2008. 07. 060.
11. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ (2008) PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179(5): 1804-1809; discussion 1809-1810. doi: 10. 1016/j. juro. 2008. 01. 013.
12. Flemming I, Cooper JS, Henson DE, et al, eds. (1998) AJCC cancer staging manual. 5 ed.
13. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, Schalken JA (2010) Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 70(1): 10-16. doi: 10. 1002/pros. 21032.
14. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG, Schalken JA (2008) Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68(11): 1215-1222. doi: 10. 1002/pros. 20781.
15. Moussa AS, Li J, Soriano M, Klein EA, Dong F, Jones JS (2009) Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 103(1): 43-48. doi: 10. 1111/j. 1464-410X. 2008. 08059. x.
16. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP (2001) Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol 165(1): 126-129. doi: 10. 1097/00005392-200101000-00031.
17. Bonin SR, Hanlon AL, Lee WR, Movsas B, al-Saleem TI, Hanks GE (1997) Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer 79(1): 75-80. doi: 10. 1002/(SICI)1097-0142(19970101)79: 1&75.
18. Harnden P, Shelley MD, Clements H, Coles B, Tyndale-Biscoe RS, Naylor B, Mason MD (2007) The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer 109(1): 13-24. doi: 10. 1002/cncr. 22388.
19. O'Malley KJ, Pound CR, Walsh PC, Epstein JI, Partin AW (2002) Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology 59(1): 85-90.
20. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Loveland KG, Bray KR (2000) Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56(2): 255-260.
21. Brassell SA, Kao TC, Sun L, Moul JW (2005) Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology 66(6): 1229-1233. doi: 10. 1016/j. urology. 2005. 06. 106.
22. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H (2006) APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52(6): 1089-1095. doi: 10. 1373/clinchem. 2005. 063289.
23. van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA (2009) Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. Prostate 69(15): 1624-1634. doi: 10. 1002/pros. 21011.